Streetbeat News

CMPS

COMPASS Pathways plc

Industry

Medical - Care Facilities

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Open

5.15

Mkt cap

345M

Volume

3.6M

High

6.04

P/E Ratio

-2.31

52-wk high

12.75

Low

4.97

Div yield

N/A

52-wk low

4.05

Several healthcare stocks experienced significant price movements in Thursday's pre-market session. Notable gainers include Autonomix Medical, Tenon Medical, and Alphatec Holdings, while Matinas BioPharma and Equillium saw substantial declines.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:09 pm

Compass Pathways has delayed the topline data readout for its COMP005 Phase 3 trial for COMP360 in treatment-resistant depression to Q2 2025 and the COMP006 data to the second half of 2026. The company is cutting its workforce by 30% to focus on the COMP360 program.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:46 am

Compass Pathways reported a Q3 2024 GAAP EPS of $(0.56), which was in line with analyst expectations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:34 am

Compass Pathways (NASDAQ:CMPS) is set to release its quarterly earnings on October 31, 2024. Analysts expect an EPS of $-0.57. Investors are keen on not just an earnings beat but also positive future guidance. Previous earnings misses have sometimes led to share price increases.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 9:03 pm

In Friday's after-market session, several healthcare stocks experienced significant price movements. Healthcare Triangle, Mira Pharmaceuticals, MEI Pharma, TuHURA Biosciences, P3 Health Partners, and OKYO Pharma saw notable gains, while Aclaris Therapeutics, Beyond Air, Qualigen Therapeutics, Nuwellis, Compass Pathways, and Helius Medical Tech experienced declines.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 8:31 pm

A new study highlights the potential of psilocybin-assisted therapy for treating depression, with millions of Americans potentially benefiting. Companies like Compass Pathways, Atai Life Sciences, and Mindset Pharma are developing psilocybin-based treatments, anticipating significant market growth if FDA approval is granted.

Portfolio Pulse from Juan Spínelli

October 07, 2024 | 8:23 pm

A study from Columbia University suggests psilocybin, found in magic mushrooms, may help treat body dysmorphic disorder (BDD). Supported by COMPASS Pathways, the study showed improved brain connectivity and symptom relief in BDD patients using COMP360, a synthetic psilocybin formulation.

Portfolio Pulse from Juan Spínelli

September 26, 2024 | 9:13 pm

The DEA is proposing significant increases in production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to support research and clinical trials. This move reflects growing interest in these substances for medical and scientific purposes.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:41 pm

The FDA has delayed the approval of MDMA-assisted psychotherapy for PTSD, requiring an additional phase 3 trial. Lykos Therapeutics is working to address the FDA's concerns. Meanwhile, other companies like Atai Life Sciences, Numinus Wellness, Compass Pathways, MindBio Therapeutics, and Awakn Life Sciences are advancing their psychedelic treatments for various psychiatric conditions.

Portfolio Pulse from Juan Spínelli

September 13, 2024 | 12:28 am

RBC Capital has reiterated its Outperform rating for Compass Pathways (NASDAQ:CMPS) and maintained a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 2:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.